StemCells, Inc. Announces Webcast to Discuss Second Quarter 2014 Financial Results

StemCells, Inc. Announces Webcast to Discuss Second Quarter 2014 Financial

NEWARK, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM), a leading stem cell company developing and commercializing
novel cell-based therapeutics and tools for use in stem cell-based research
and drug discovery, announced today that it will release financial results for
the second quarter ended June 30, 2014 after the market close on Tuesday,
August 12. StemCells will host a conference call and webcast to discuss its
results and an update on its business at 1:30 p.m. Pacific Daylight Time (4:30
p.m. Eastern Daylight Time) the same day.

Interested parties are invited to listen to the call over the Internet by
accessing the Investors section of the Company's website at Webcast participants should allot extra time before the
webcast begins to register and, if necessary, download and install audio

Event: Q2 2014 Financial Results Conference Call / Webcast

Date: Tuesday, August 12, 2014 

Time:1:30 PM PDT (4:30 PM EDT)

Live webcast:

An archived version of the webcast will be available for replay on the
Company's website beginning approximately two hours following the conclusion
of the live call and continuing for a period of 30 days.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC®
cells (purified human neural stem cells), is currently in development as a
potential treatment for a broad range of central nervous system disorders.In
a PhaseI clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children, the Company has shown preliminary evidence
of progressive and durable donor-derived myelination in all four patients
transplanted with HuCNS-SC cells.The Company has completed enrollment of a
Phase I/II clinical trial in chronic spinal cord injury in Switzerland and
Canada and has reported positive interim data for the first three
patients.The Company is also conducting a Phase I/II clinical trial in dry
age-related macular degeneration (AMD) in the United States. In addition, the
Company is pursuing preclinical studies in Alzheimer's disease, with support
from the California Institute for Regenerative Medicine (CIRM).StemCells
also markets stem cell research products, including media and reagents, under
the SC Proven® brand.Further information about StemCells is available at

Apart from statements of historical fact, the text of this press release
constitutes forward-looking statements within the meaning of the U.S.
securities laws, and is subject to the safe harbors created therein. These
forward-looking statements speak only as of the date of this news release. The
Company does not undertake to update any of these forward-looking statements
to reflect events or circumstances that occur after the date hereof. Such
statements reflect management's current views and are based on certain
assumptions that may or may not ultimately prove valid. The Company's actual
results may vary materially from those contemplated in such forward-looking
statements due to risks and uncertainties to which the Company is subject,
including those described under the heading "Risk Factors" in the Company's
Annual Report on Form 10-K for the year ended December 31, 2013 and in its
subsequent reports on Forms 10-Q and 8-K.

CONTACT: Greg Schiffman
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128
         Andrea Flynn
         Russo Partners
         (646) 942-5631

company logo
Press spacebar to pause and continue. Press esc to stop.